Cornerstone Planning LLC Invests $3.08 Million in Merck & Co., Inc. $MRK

Cornerstone Planning LLC purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 29,204 shares of the company’s stock, valued at approximately $3,085,000.

Several other large investors have also made changes to their positions in MRK. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $25,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. in the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth $26,000. United Financial Planning Group LLC acquired a new position in shares of Merck & Co., Inc. during the 3rd quarter worth $31,000. Finally, High Note Wealth LLC raised its holdings in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $114.04 on Friday. The firm has a market capitalization of $281.65 billion, a PE ratio of 32.12, a PEG ratio of 2.56 and a beta of 0.21. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $125.14. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The firm’s fifty day simple moving average is $115.94 and its 200 day simple moving average is $113.60.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the previous year, the business earned $2.22 EPS. The business’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 3.0%. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Analysts Set New Price Targets

Several research firms recently issued reports on MRK. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Wells Fargo & Company reduced their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. UBS Group upped their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Finally, Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.